Clinical Trials Browser

INDUSTRY × Ovarian Neoplasms × Temozolomide × Clear all

NCT05417594 2026-03-12

CERTIS1

Phase 1/2 Recruiting

BreastCNSGastrointestinalGenitourinaryGynecologic

Astrocytoma, Breast Neoplasms, Fallopian Tube Neoplasms, Glioma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms

NCT01618136 2023-06-18

An Open-Label, Multicenter, Phase 1/2 Study of Poly(ADP-Ribose) Polymerase (PARP) Inhibitor E7449 as Single Agent in Subjects With Advanced Solid Tumors or With B-cell Malignancies and in Combination With Temozolomide (TMZ) or With Carboplatin and Paclitaxel in Subjects With Advanced Solid Tumors

Phase 1/2 Completed

BreastGynecologicLymphoidOther hematologic neoplasm

Ovarian Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Triple Negative Breast Neoplasms

NCT04851834 2022-12-20

NTX-301 Monotherapy in Advanced Solid Tumours and in Combination With Platinum-based Chemotherapy in Advanced Ovarian & Bladder Cancer and in Combination With Temozolomide in High-grade Glioma

Phase 1/2 Terminated

CNSGenitourinaryGynecologic

Urinary Bladder Neoplasms, Glioma, Ovarian Neoplasms

NCT02836028 2018-09-18

A Study Evaluating Talazoparib in Relapsed Ovarian, Fallopian Tube, and Peritoneal Cancer

Phase 2 Withdrawn

Ovarian Neoplasms

NCT01113957 2018-06-06

A Trial of ABT-888 in Combination With Temozolomide Versus Pegylated Liposomal Doxorubicin Alone in Ovarian Cancer

Phase 2 Completed

Ovarian Neoplasms

NCT00526617 2017-11-21

A Phase I Study of ABT-888 in Combination With Temozolomide in Cancer Patients

Phase 1 Completed

BreastDermatologicGastrointestinalGynecologic

Breast Neoplasms, Fallopian Tube Neoplasms, Carcinoma, Hepatocellular, Melanoma, Ovarian Neoplasms